Combination of adjuvants: the future of vaccine design. (July 2013)

• Record Type: Journal Article
• Authors: Mount, Adele; Koernig, Sandra; Silva, Anabel; Drane, Debbie; Maraskovsky, Eugene; Morelli, Adriana Baz
• Is Part Of: Expert review of vaccines. Volume 12:Number 7(2013)
• Page Start: 733
• Page End: 746
• Publication Date: 2013-07
• Subjects: adjuvants -- ISCOMATRIX® adjuvant -- Toll-like receptor -- vaccines; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/14760584.2013.811185
• Languages: English
• ISSNs: 1476-0584

Abstract

It is thought that the development of vaccines for the treatment of infectious diseases and cancer is likely to be achieved in the coming decades. This is partially due to a better understanding of the regulatory networks connecting innate with adaptive immune responses. The innate immune response is triggered by the recognition of conserved pathogen-associated molecular patterns by germ line-coded pattern recognition receptors. Several families of pattern recognition receptors have been characterized, including Toll-like receptors and nucleotide-binding domain receptors. The identification of their ligands has driven the development of novel adjuvants many of which have been tested in vaccine clinical trials. Here, the authors review recent preclinical data and clinical trial results supporting the view that combinations of adjuvants are the way forward in vaccine design. Multiadjuvanted vaccines can stimulate the broad and robust protective immune responses required to fight chronic infectious diseases and cancer.